Beth Nally

mdpi.com/2072-6694/18/5… @tompowles1

Sharing our recent work: mdpi.com/2072-6694/18/5… With increasing complexity in mRCC sequencing, this exploratory analysis suggests improved VEGF outcomes after prior IOvsVEGF. Findings are hypothesis generating, but relevant given challenges of prospective ≥2L RCTs.

R3 RAMPART QOL data #GU25 : Durva/tremi is associated with serious short term tox and life changing toxicity in subgroups of patients, which will effect QOL in the adjuvant setting. But the primary QOL endpoint for adjuvant durva/tremi vs surveillance showed no difference in arms. Subsequent multiple analysis did show some differences, but QOL tools in the adjuvant setting for immune therapy seem inaccurate @OncoAlert @montypal @DrChoueiri @crisbergerot @BethN01

As ICIs expand into perioperative space, conversation is evolving beyond survival benefit. How do we: 🔵 Select pts most likely to benefit? 🔵 Measure chronic immune toxicity? 🔵 Quantify long term QoL impact in cured pts? Important review highlighting some of these challenges.

On #WorldCancerDay, I'm incredibly proud to be undertaking my PhD at ⁦@QMBCI⁩. Cancer affects many of us through our patients, colleagues, friends and families. Very grateful to be part of a community committed to making a difference. linkedin.com/posts/elizabet…

Great to share the stage with @BethN01, @LauBuisseret, and Hong Wan for a fun and insightful session on ADCs, exploring the question: “Are ADCs immunotherapies?” #ESMOimmuno25

Thank you to @myESMO & #ESMOImmuno25 for the opportunity to open the ADC session and discuss how these drugs are driving transformative change in cancer management. Honoured to share the stage with global experts across academia and industry @sciqst @LauBuisseret

Randomized trials testing ctDNA and HER-2 biomarkers in bladder cancer both delivered positive results with OS #ESMO25 . Here @scocmem described how these and other biomarkers are changing bladder cancer. @PGrivasMDPhD @OncoAlert #uromigosLive

First ph3 RCT showing PFS benefit with adjuvant combination therapy in RCC! Growing evidence to support periop therapy following host of negative studies. Work to be done in identifying those most likely to benefit from therapy

IMvigor011 marks a major step forward for perioperative cancer care. Using ctDNA to identify who truly benefits from adjuvant therapy spares others unnecessary and potentially life long toxicity, improves quality of life and reduces healthcare burden.

1/2 KN905 Enfortumab Vedotin + Pembro continues to transform bladder cancer in spectacle fashion. In cisplatin ineligible operable disease it beats cystectomy with EFS HR 0.4, OS HR 0.5. pCR of 57% is much ⬆️ than anything before #ESMO25 pCR> 50% questions unselected surgery

Incredibly exciting data in perioperative #BladderCancer yesterday at #ESMO25 NAj EV-Pem 57% pCR in the cis-ineligible population. Can’t wait to see what’s next with the upcoming randomized ph3 #KeynoteB15 🔬 Might we be able to avoid cystectomy in these patients?

Biomakers in RCC have been disappointing. RNA immune & angio signatures were identified in Immotion150 @brian_rini Cabozantinib + Nivolumab in RNA Cluster 1/2 (angio) in M1 RCC shows great response rates in these patients. We can do these difficult studies #ESMO25 @OncoAlert

Excited to be at my first ESMO in wonderful Berlin! #ESMO25

Dr Elizabeth Nally @BethN01 from @BartsECMC presents at #GU25 QoL tools and toxicity definitions require re-evaluation in the IO era. She validates novel tools within PRISM, a ph2 RCT. Response to Tx appears to influence QoL more than any other parameter, incl life changing tox

Also some great work led by some of our Trainees @AlfredSo12 & @maxi_beth attending their first @BTOGORG hopefully they’re hooked #RespIsBest 🫁

@Tanith44 Superstar! The best news ✨

Delighted to accept my top choice job of Medical Oncology at St Barts Hospital - feeling really overwhelmed and grateful that I get to do this. Thank you so much to everyone whose given me endless advice, support and interview practice. Here’s to the next chapter!

@nikkismallcombe 🥳🥳🥳

BEYOND ecstatic to get my Respiratory Training number in North Central and East London!!!! 🫁 ❤️ #respisbest

@PassportIRL my passport tracker says there has been a problem with my application and I will be emailed but I haven’t received said email. My docs have been returned to me. I sent application in August 2021!

Brilliant time at my first @ACPUK trainee weekend. Very thankful we can all be there in person..hopefully many more to come! #ACP21